Electroporation-enhanced transdermal diclofenac sodium delivery into the knee joint in a rat model of acute arthritis
Purpose: Since electroporation (EP) can increase the permeability of biological membranes, we hypothesized that it offers an opportunity to enhance the transdermal delivery of drugs for intra-articular indications. Our aim was to compare the anti-inflammatory and analgesic efficacy of EP-combined to...
Elmentve itt :
Szerzők: | |
---|---|
Dokumentumtípus: | Cikk |
Megjelent: |
2018
|
Sorozat: | DRUG DESIGN DEVELOPMENT AND THERAPY
12 |
doi: | 10.2147/DDDT.S161703 |
mtmt: | 3394721 |
Online Access: | http://publicatio.bibl.u-szeged.hu/13810 |
LEADER | 03462nab a2200349 i 4500 | ||
---|---|---|---|
001 | publ13810 | ||
005 | 20180908145514.0 | ||
008 | 180908s2018 hu o 0|| zxx d | ||
022 | |a 1177-8881 | ||
024 | 7 | |a 10.2147/DDDT.S161703 |2 doi | |
024 | 7 | |a 3394721 |2 mtmt | |
040 | |a SZTE Publicatio Repozitórium |b hun | ||
041 | |a zxx | ||
100 | 1 | |a Hartmann Petra | |
245 | 1 | 0 | |a Electroporation-enhanced transdermal diclofenac sodium delivery into the knee joint in a rat model of acute arthritis |h [elektronikus dokumentum] / |c Hartmann Petra |
260 | |c 2018 | ||
300 | |a 1917-1930 | ||
490 | 0 | |a DRUG DESIGN DEVELOPMENT AND THERAPY |v 12 | |
520 | 3 | |a Purpose: Since electroporation (EP) can increase the permeability of biological membranes, we hypothesized that it offers an opportunity to enhance the transdermal delivery of drugs for intra-articular indications. Our aim was to compare the anti-inflammatory and analgesic efficacy of EP-combined topical administration of diclofenac sodium hydrogel (50 mg mL(-1) in 230 microL volume) with that of an equivalent dose of oral (75 mg kg(-1)) and simple topical administration. Methods: Arthritis was induced with the injection of 2% lambda-carrageenan and 4% kaolin into the right knee joints of male Sprague Dawley rats. EP was applied for 8 min with 900 V high-voltage pulses for 5 ms followed by a 20 ms break. Drug penetration into the synovial fluid and plasma was detected by high-performance liquid chromatography. Leukocyte-endothelial interactions were visualized by intravital videomicroscopy on the internal surface of the synovium. Inflammation-induced thermal and mechanical hyperalgesia reactions, knee joint edema, and inflammatory enzyme activities were assessed at 24 and 48 h after arthritis induction. Results: EP significantly increased the plasma level of diclofenac as compared with the topical controls 10 min after the 2% lambda-carrageenan and 4% kaolin injection. Increased leukocyte-endothelial interactions were accompanied by joint inflammation, which was significantly reduced by oral and EP diclofenac (by 45% and by 30%, respectively) and only slightly ameliorated by simple topical diclofenac treatment (by 18%). The arthritis-related secondary hyperalgesic reactions were significantly ameliorated by oral and EP-enhanced topical diclofenac treatments. The knee cross-section area (which increased by 35%) was also reduced with both approaches. However, simple topical application did not influence the development of joint edema and secondary hyperalgesia. Conclusion: The study provides evidence for the first time of the potent anti-inflammatory and analgesic effects of EP-enhanced topical diclofenac during arthritis. The therapeutic benefit provided by EP is comparable with that of oral diclofenac; EP is a useful alternative to conventional routes of administration. | |
700 | 0 | 1 | |a Butt Edina |e aut |
700 | 0 | 1 | |a Fehér Ágnes |e aut |
700 | 0 | 1 | |a Szilágyi Ágnes |e aut |
700 | 0 | 1 | |a Jász Kurszán Dávid |e aut |
700 | 0 | 1 | |a Balázs Boglárka |e aut |
700 | 0 | 1 | |a Bakonyi Mónika |e aut |
700 | 0 | 1 | |a Berkó Szilvia |e aut |
700 | 0 | 1 | |a Erős Gábor |e aut |
700 | 0 | 1 | |a Boros Mihály |e aut |
700 | 0 | 1 | |a Horváth Gyöngyi |e aut |
700 | 0 | 1 | |a Varga Endre |e aut |
700 | 0 | 1 | |a Csányi Erzsébet |e aut |
856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/13810/1/Hartmann_et_al_dddt_161703_electroporation_enhanced_transdermal_drug_delivery_into_the__062618_u.pdf |z Dokumentum-elérés |